Loading
A phase 2 trial of APG-115 in hodgkin lymphoma, run by Ascentage Pharma Group Inc., now recruiting.
A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL is a phase 2 interventional study registered as NCT04496349 by Ascentage Pharma Group Inc., with 78 participants planned, started 2021-07-12 and due to reach its primary completion in 2026-05-31. Interventions recorded: APG-115 and APG-2575.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Ascentage Pharma and the tag pipeline.
Shares Ascentage Pharma and the tag pipeline.
Shares Ascentage Pharma and the tag pipeline.
Shares Ascentage Pharma and the tag pipeline.
Shares Ascentage Pharma and the tag pipeline.
Shares T-cell prolymphocytic leukaemia and the tag pipeline.
Shares Hodgkin lymphoma and the tag pipeline.
Shares Hodgkin lymphoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/